06th week of 2015 patent applcation highlights part 50 |
Patent application number | Title | Published |
20150038392 | ANIONIC MICELLES WITH CATIONIC POLYMERIC COUNTERIONS SYSTEMS THEREOF - The invention relates to a polymer-micelle complex. The polymer-micelle complexes include a negatively charged micelle that is electrostatically bound to a water-soluble polymer bearing a positive charge. The polymer does not comprise block copolymer, latex particles, polymer nanoparticles, cross-linked polymers, silicone copolymer, fluorosurfactant, or amphoteric copolymer. The compositions do not form a coacervate, and do not form a film when applied to a surface. | 2015-02-05 |
20150038393 | LAUNDRY DETERGENT PARTICLES - The present invention provides lenticular or disc detergent particles comprising (i) surfactant, (ii) inorganic salts and (iii) dye, wherein the inorganic salts and the dye are present on the detergent particle as a coating and the surfactant is present as a core. The dye containing coating gives reduced staining. | 2015-02-05 |
20150038394 | METHOD OF MAKING DETERGENT COMPOSITIONS COMPRISING POLYMERS - A process of making a granular detergent composition comprising the steps of:
| 2015-02-05 |
20150038395 | METHOD OF MAKING DETERGENT COMPOSITIONS COMPRISING POLYMERS - A process of making a granular detergent composition comprising the steps of:
| 2015-02-05 |
20150038396 | METHOD OF MAKING GRANULAR DETERGENT COMPOSITIONS COMPRISING SURFACTANTS - A process of making a granular detergent composition comprising the steps of:
| 2015-02-05 |
20150038397 | METHOD OF MAKING GRANULAR DETERGENT COMPOSITIONS COMPRISING POLYMERS - A process of making a granular detergent composition comprising the steps of:
| 2015-02-05 |
20150038398 | LAUNDRY DETERGENT PARTICLE - The present invention provides lenticular or disc detergent particles comprising surfactant, inorganic salts and pigment, wherein the inorganic salts are present on the detergent particles as a coating and the surfactant and the pigment are present as a core. The particles show reduced staining. | 2015-02-05 |
20150038399 | Compositions Containing Secondary Paraffin Sulfonate And Alcohol Alkoxylate - The invention relates to compositions containing a) 45 to 65 wt. % of one or more secondary paraffin sulfonates with 8 to 22 carbon atoms, b) 1 to 10 wt. % of one or more alcohol alkoxylates which are produced from the reaction of alcohols R—OH, wherein R is an alkyl group with 4 to 8 carbon atoms, with alkoxylating agents selected from ethylene oxide, propylene oxide, or mixtures thereof and which contain on average 1 to 10 mol of structural units derived from the alkoxylating agents per 1 mol of structural units derived from the alcohols, and c) 25 to 52 wt. % water, in relation to the total weight of the composition in each case. The compositions can be used in an advantageous manner for producing washing and cleaning agents. | 2015-02-05 |
20150038400 | Compositions, the Preparation and Use Thereof - The present teachings provide new compositions comprising polycations and polycations, and the preparation and use of these new compositions. In one aspect, the new compositions are complex coacervates. The compositions described herein can have several desired properties, including, low interfacial tension in water, adjustable cohesive strength, antimicrobial activity, suitability for dissolution at or near physiological pH, biocompatiblility, and/or biodegradability. The compositions can have the ability of promoting cell attachment, cell adhesion, cell migration, cell differentiation, and/or morphogenesis. Thus, in various embodiments, the complex coacervates can be used in water-based applications, for example, in the body. | 2015-02-05 |
20150038401 | CARRIER FOR TARGETING NERVE CELLS - The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by | 2015-02-05 |
20150038402 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS - The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor- | 2015-02-05 |
20150038403 | Compounds That Bind to the Erythropoietin Receptor - The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin. | 2015-02-05 |
20150038404 | MACROCYCLIC COMPOUNDS - This invention relates to novel macrocyclic compounds (e.g., those delineated in the formulae herein), pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the protease elastase. | 2015-02-05 |
20150038405 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ARTERIOSCLEROSIS - The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis. | 2015-02-05 |
20150038406 | PHARMACEUTICAL FORMULATIONS OF TRANEXAMIC ACID AND THEIR USE - The present invention relates to pharmaceutical formulations comprising tranexamic acid, kits thereof, and methods for treating bleeding by local administration. | 2015-02-05 |
20150038407 | OLIGOPEPTIDE COMPOUNDS AND USES THEREOF - The present invention relates to novel agents, pharmaceutical compositions containing them, and theft use in therapy, particularly anti-microbial and anti-cancer therapy. In particular, the present invention relates to novel peptide-based compounds based on SEQ ID NO: 40 which have surprisingly been shown to have inhibitory effects on the growth and/or viability of cells, particularly bacterial and cancer cells. Also provided are therapeutic and non-therapeutic methods which include the use of peptides of the invention. | 2015-02-05 |
20150038408 | Polypeptides for treating and/or limiting influenza infection - The present invention provides polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier. Additionally, the present invention provides methods for treating and/or limiting an influenza infection, methods for diagnosing an influenza infection, or monitoring progression of an influenza infection, methods for identifying candidate influenza vaccines, and methods for identifying candidate compounds for treating, limiting, and/or diagnosing influenza infection. | 2015-02-05 |
20150038409 | Leptin Compositions and Methods for Treating Progressive Cognitive Function Disorders Resulting from Accumulation of Neurofibrillary Tangles and Amyloid Beta - The present disclosure provides compositions containing a leptin product and methods of clinical therapy and diagnostic methods for progressive cognitive disorders. According to one aspect, the described invention provides a method for treating a progressive cognitive disorder. According to another aspect, the described invention provides a method for improving resilience of cognitive function in a subject in need thereof. According to another aspect, the described invention provides a method for identifying an effective therapeutic agent for treating a progressive cognitive dysfunction disease or disorder that results from at least one of accumulation of Aβ, hyperphosphorylation of tau, or accumulation of neurofibrillary tangles. | 2015-02-05 |
20150038410 | Heterocyclic Nitrogen Containing Polymer Coated Analyte Monitoring Device and Methods of Use - The present invention is directed to membranes composed of heterocyclic nitrogen groups, such as vinylpyridine and to electrochemical sensors equipped with such membranes. The membranes are useful in limiting the diffusion of an analyte to a working electrode in an electrochemical sensor so that the sensor does not saturate and/or remains linearly responsive over a large range of analyte concentrations. Electrochemical sensors equipped with membranes described herein demonstrate considerable sensitivity and stability, and a large signal-to-noise ratio, in a variety of conditions. | 2015-02-05 |
20150038411 | RELAXIN FOR TREATING PATIENTS AFFLICTED OF IMPAIRED GLUCOSE TOLERANCE - A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed. | 2015-02-05 |
20150038412 | ENHANCED GLYCEMIC CONTROL USING AD36E4ORF1 AND AKT1 INHIBITOR - This invention generally relates to methods for improving glycemic control by administering an Ad36 composition and an AKT1 inhibitor. | 2015-02-05 |
20150038413 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME - A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed. | 2015-02-05 |
20150038414 | Organic Compounds - A pharmacutical composition for parenteral administration of a somatostatin analogue salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid. | 2015-02-05 |
20150038415 | PROCESS FOR THE MANUFACTURING OF A DRUG DELIVERY SYSTEM BASED ON A POLYMER COMPRISING A DISPERSED BIOACTIVE AGENT - Process for the manufacturing of a drug delivery system based on a polymer comprising dispersed bioactive agent via the following process steps: (a) dissolving a polymer in an organic solvent (b) mixing the dissolved polymer with the bioactive agent (c) laminating the mixture between two polymer sheets, whereby at least one of the sheets is permeable to the organic solvent, to provide a film whereby the film can be further processed into the drug delivery system. The drug delivery system is suitable for implantation or injection and comprises fibres, rods, discs, coatings, tubes, films or rolled films. The polymer comprising the dispersed bioactive agent is a biostable, bioerodable or biodegradable polymer selected from the group consisting of polyesteramides, polythioesters, polyesterurethanes, polyesterurea's, PLLA, PLGA, polyesters, polyanhydrides, polycarbonates, polyurethanes, poly (amino acids), polypeptides, polyamides, polysaccharides, polyethers, polysulfones, poly(meth)acrylates, polysiloxanes, polyolefins. | 2015-02-05 |
20150038416 | NOVEL GLP-1 RECEPTOR MODULATORS - The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ | 2015-02-05 |
20150038417 | GLP-1 Agonists - A method for the prevention or treatment of alcoholism and drug addiction comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 agonist. | 2015-02-05 |
20150038418 | NATRIURETIC PEPTIDE COMPOSITIONS AND METHODS OF PREPARATION - Therapeutic compositions containing natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing natriuretic peptides are further described. | 2015-02-05 |
20150038419 | SIMUKUNIN - The present invention includes a novel protein, also referred to herein as simukunin, that inhibits the function of several physiologically important enzymes. Simukunin is a potent inhibitor of the blood coagulation cascade, inhibiting Factor Xa and functioning as an efficient anticoagulant. Simukunin also inhibits the serine proteases elastase and cathepsin and demonstrates anti-inflammatory properties. Also included are methods of making and using simukunin. | 2015-02-05 |
20150038420 | METHODS FOR TREATING PROPERDIN-RELATED DISEASES OR DISORDERS - The present invention relates to methods for treating or preventing a properd related disease or disorder in a subject in need thereof, or for reducing mortality of a subject suffering from a properdin-related disease or disorder, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a properdin protein. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments. | 2015-02-05 |
20150038421 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 2015-02-05 |
20150038422 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE - Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient. | 2015-02-05 |
20150038423 | DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN - Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided. | 2015-02-05 |
20150038424 | FORMULATIONS AND KITS FOR FORMING BIOADHESIVE MATRICES - A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed. | 2015-02-05 |
20150038425 | COLLAGEN-BINDING SYNTHETIC PEPTIDOGLYCANS FOR USE IN VASCULAR INTERVENTION - This invention relates to collagen-binding synthetic peptidoglycans. More particularly, this invention relates to collagen-binding synthetic peptidoglycans for use in vascular intervention procedures. The invention also relates to kits comprising such collagen—binding synthetic peptidoglycans and catheters or stents. | 2015-02-05 |
20150038426 | Monomeric and Dimeric Forms of Adiponectin Receptor Fragments and Methods of Use - Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, disclosed herein are methods of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER | 2015-02-05 |
20150038427 | COLLAGEN-BINDING SYNTHETIC PEPTIDOGLYCANS FOR WOUND HEALING - Methods and compositions for promoting wound healing in a patient by administering a collagen-binding synthetic peptidoglycan to the patient are described. Additionally, methods and compositions are described for decreasing scar formation in a patient by administering a collagen-binding synthetic peptidoglycan to the patient. | 2015-02-05 |
20150038428 | ORGANOGELS AND EMULSIONS FOR BIOLOGICAL AND NON-BIOLOGICAL APPLICATIONS - The present invention relates to organogels and emulsions based on ultrasmall self-assembling peptides. It further relates to methods for producing such organogels and emulsions as well as to the use of the organogels and emulsions in biological and non-biological applications. | 2015-02-05 |
20150038429 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4′-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment. | 2015-02-05 |
20150038430 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease. | 2015-02-05 |
20150038431 | INFLAMMATORY EYE DISORDERS - Provided herein are methods of evaluating efficacy of a treatment in a subject having eye inflammation (e.g., a subject having dry eye syndrome) and selecting a subject for participation in a clinical study. Also provided are methods of treating a subject having eye inflammation (e.g., a subject having dry eye syndrome). | 2015-02-05 |
20150038432 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION - The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2α, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2α and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction. | 2015-02-05 |
20150038433 | Clusterin Pharmaceuticals and Treatment Methods Using the Same - Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7. | 2015-02-05 |
20150038434 | Melanocortin-1 Receptor-Specific Cyclic Peptides - Melanocortin receptor-specific cyclic peptides of the formula | 2015-02-05 |
20150038435 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF - The present invention is related to N-terminally fatty acid modified peptides or oligopeptides and pharmaceutical compositions comprising such. | 2015-02-05 |
20150038436 | TAILORED GLYCOPOLYMERS AS ANTICOAGULANT HEPARIN MIMETICS - The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods. | 2015-02-05 |
20150038437 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE - The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens. | 2015-02-05 |
20150038438 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE - The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens. | 2015-02-05 |
20150038439 | METHOD FOR PREPARING SUSPENSIONS OF LOW-SOLUBILITY MATERIALS - A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process. | 2015-02-05 |
20150038440 | DIHYDROFURAN AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS - This invention recites dihydrofuran substituted azetidine derivatives of Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in mammals and birds. The substituents A, R | 2015-02-05 |
20150038441 | KIT-IN-PARTS FOR CLEANING AND TREATING EARS OF COMPANION ANIMALS - The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of otitis externa, application and dosage information, cannules, cotton swabs, gauzes and information about the cleaning and maintenance ears of a companion animal. | 2015-02-05 |
20150038442 | POLYELECTROLYTE COMPLEXES COMPRISING NATAMYCINE AND/OR PHOSPHITE FOR BIOCIDE ENHANCEMENT - The invention relates to a composition comprising a polyelectrolyte complex of a polyanion and a polycation, further comprising at least one biocide comprising natamycin and/or phosphite. A preferred composition comprises lignosulfonate and chitosan, preferably in relative amount of from 1:2 to 60:1 (w/w). The invention further relates to methods for generating a composition according to the invention, and to uses of a mixture according to the invention for protecting an agricultural plant or plant part against a pathogen. | 2015-02-05 |
20150038443 | Transcription Factor Inhibitors and Related Compositions, Formulations and Methods - The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general and breast cancer initiating cells in particular. | 2015-02-05 |
20150038444 | TREATING MYELODYSPLASTIC SYNDROMES USING LENALIDOMIDE - Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine. | 2015-02-05 |
20150038445 | METHODS AND COMPOSITIONS FOR TREATING PAIN - The disclosure provides a new use of adenosine analogs for the treatment of pain through activation of neurokinin 1 (NK1) receptor signaling pathway, thereby inducing the activation of M-type potassium channel to induce outward currents. A method and pharmaceutical composition for treating pain comprising an adenonsine analog that activates NK1 receptor signaling, thereby inducing outward current are also provided. | 2015-02-05 |
20150038446 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION - The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor. | 2015-02-05 |
20150038447 | ORGAN PROTECTION, PRESERVATION AND RECOVERY - This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent. The methods may further include postconditioning the cell, tissue or organ. | 2015-02-05 |
20150038448 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE - The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A | 2015-02-05 |
20150038449 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 2015-02-05 |
20150038450 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER - Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for the treatment of cancers such as acute myeloid leukemia. | 2015-02-05 |
20150038451 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs. | 2015-02-05 |
20150038452 | Methods of Treating Optic Disorders - The present invention relates to methods for treating optic disorders or for reducing or alleviating the signs, symptoms, or pathological conditions related to such optic disorders. In particular, methods are provided for treating optic disorders, or reducing the symptoms thereof, the methods involving the administration of one or more downstream folate compounds and/or methyl-B12. In one particular embodiment, the method comprises administration of L-methylfolate. In other embodiments, the method involves administering both L-methylfolate and methyl-B12. In still further embodiments, the method further involves reducing dietary intake of folic acid. In certain embodiments, the method further involves identifying a subject organism with a malfunction in one or more of the folate or B4 cycles. In certain embodiments, such a malfunction is one or more of the C677T and A1298C mutations. In still further embodiments, the method further involves identifying a subject organism that is deficient in vitamins B-12 and D3 but which possesses excess homocysteine. | 2015-02-05 |
20150038453 | PREPARATION FOR USE OF ASPARTATE AND VITAMIN B12 OR BIOTIN FOR REGULATING KETONE BODIES - It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents. | 2015-02-05 |
20150038454 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE - Compositions comprising an antimicrobial effective concentration of sucralose and methods of using for treating pharyngeal and other bacterial conditions. | 2015-02-05 |
20150038455 | HEPARAN SULFATE/HEPARIN MIMETICS WITH ANTI-CHEMOKINE AND ANTI-INFLAMMATORY ACTIVITY - The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods. | 2015-02-05 |
20150038456 | Stable Hydrogel Compositions Including Additives - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 2015-02-05 |
20150038457 | COMPOSITION COMPRISING HYALURONIC ACID AND MEPIVACAINE - Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin. | 2015-02-05 |
20150038458 | Skin-Protecting Alkalinity-Controlling Composition and the Use Thereof - A skin-protecting alkalinity-controlling composition comprises one or more carboxylic acid polysaccharides. Said compositions are capable of providing buffering, and thus avoiding a major increase in the pH of an aqueous system and/or are capable of reducing the pH of aqueous systems, in which alkalinity is formed as a result of chemical and/or biological reactions. The compositions may be used in personal care products, such as skin creams and lotions, hygiene products, wound care products, fabric treating products etc. | 2015-02-05 |
20150038459 | PROTEIN CONTAINING FOOD STUFFS - Nutritious protein-containing foodstuffs can be prepared in the form of gels, including protein gel and fruit purees that contain all essential amino acids. A protein gel for use as a foodstuff is prepared by heating an aqueous protein solution to between 160 and 185 degrees Fahrenheit at an acidic pH between 2.85 and 3.5, the protein solution having a viscosity greater than 100 centipoise and containing a protein at a concentration of 10-20% w/w, the protein being at least one of a whey protein isolate and a liquid soy protein isolate, the protein gel having a viscosity of between 10,000 and 1,000,000 centipoise. | 2015-02-05 |
20150038460 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor - The invention relates to novel compounds of Formula I: | 2015-02-05 |
20150038461 | THIOPYRIMIDINECARBOXAMIDES AS CXCR1/2 MODULATORS - There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide compound. More specifically, there is disclosed a CXCR1/2 inhibitor useful for treating a variety of inflammatory and neoplastic disorders. | 2015-02-05 |
20150038462 | OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS - A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS:1-4. Exposure of cells infected with a flavivirus to the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a T | 2015-02-05 |
20150038463 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES - Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba(bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogues of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life in vivo due to the stability of the C—P bond. When administered to calsequestrin-overexpressing mice (a genetic model of heart failure) via a mini-osmotic pump (Alzet), some analogues significantly increased intact heart contractile function in vivo, as assessed by echocardiography-derived fractional shortening (FS) as compared to vehicle-infused mice. The range of carbocyclic nucleotide analogues for treatment of heart failure has been expanded. | 2015-02-05 |
20150038464 | METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION - Disclosed herein are methods of increasing retinal responsiveness to light in a subject, such as a subject with retinal degeneration. The disclosed methods include administering one or more compounds that decrease or inhibit γ-aminobutyric acid (GABA) signaling to a subject with retinal degeneration. In some embodiments, the methods include selecting a subject with retinal degeneration and administering a γ-aminobutyric acid C (GABA | 2015-02-05 |
20150038465 | USE OF DERIVATIVE COMPOUNDS OF1,3-BENZODIOXOLE IN INSECTICIDAL COMPOSITIONS - The invention relates to the use of a derivative compound of 1,3-benzodioxole of formula (I) wherein R is a linear or branched (C | 2015-02-05 |
20150038466 | PAIN RELIEF COMPOUNDS - The present invention relates to the use of compounds for the treatment or prevention of pain in mammals, in particularly in human beings, and also to a process for preparing these compounds. | 2015-02-05 |
20150038467 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHOSPHATIDYLSERINE AND CURCUMIN - The present invention describes and claims stable pharmaceutical compositions and/or food supplements based on phosphatidylserine (PS) and curcumin, which are consequently devoid of degradation products, for use in the prevention and treatment of disorders associated with brain aging, and in the prevention and treatment of osteoporosis and/or osteoarthritis. | 2015-02-05 |
20150038468 | ESTROGEN ANTAGONISTS AS TREATMENTS FOR SCLEROSING DISORDERS - The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions. | 2015-02-05 |
20150038469 | COMPOSITIONS FOR TREATMENT OF CARDIOMETABOLIC DISORDERS - The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins. | 2015-02-05 |
20150038470 | BIOCIDE COMPOSITIONS - Disclosed are biocide compositions. The compositions are useful in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. Also disclosed are methods of using the compositions, particularly in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. | 2015-02-05 |
20150038471 | PROCESS FOR PREVENTING OR MITIGATING BIOFOULING - Biofouling may be prevented or at least mitigated by employing a cinnamaldehyde additive to augment the affect of the conventional biocide. Exemplary cinnamaldehyde additives include, but are not limited to, cinnamaldehyde, cinnamic acid and cinnamyl alcohol. A cinnamaldehyde additive by itself, in some embodiments, may also inhibit biofouling. | 2015-02-05 |
20150038472 | USE OF THERAPEUTICALLY EFFECTIVE LIPIDS AND METHOD FOR PRODUCING ORGAN-/TISSUE-SPECIFIC THERAPEUTICALLY EFFECTIVE LIPIDS - The use of therapeutically active lipids for organ/tissue-specific enrichment for the treatment of inflammatory, ischemic or degenerative disorders and/or for stimulating a regeneration is arranged and developed such that the lipids are bound on application to carrier molecules for which cell-specific uptake systems in the cells of the organs and/or tissue exist. In addition, a method of producing organ/tissue-specific therapeutically active lipids for treatment of inflammatory, ischemic or degenerative disorders and/or stimulation of a regeneration, in particular for treating inflammatory liver disorders, is claimed, which is arranged and developed such that lysophosphatidylethanolamine (LysoPE) is coupled to the carboxyl group of ursodeoxycholate (UrsoDOCA) converted to an ester to give a LysoPE-DOCA compound. | 2015-02-05 |
20150038473 | STABLE POVIDONE-IODINE COMPOSITIONS WITH STEROIDS OR NON-STEROIDAL ANTI-INFLAMMATORIES - Disclosed are stable compositions comprising povidone-iodine and a steroid, and methods of making and using such compositions. Also disclosed herein are stable compositions comprising povidone-iodine and an NSAID, and methods of making and using such compositions. | 2015-02-05 |
20150038474 | ORGANIC COMPOUNDS - Optionally substituted 3-(thio, sulfinyl or sulfonyl)-7,8-dihydro-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or a substituted 3-(thio, sulfinyl or sulfonyl)-7,8,9-trihydro-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. | 2015-02-05 |
20150038475 | TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier. | 2015-02-05 |
20150038476 | Method for Treating Gynecological Diseases - The present invention relates generally to a combination for use in the treatment of gynaecological diseases and associated disabling symptoms thereof, in a subject in need thereof, said pharmaceutical combination for use comprising co-administering a suitable pharmaceutical composition for oral administration comprising a first progesterone receptor modulator and a pharmaceutical composition suitable for vaginal and/or intrauterine administration comprising a second progesterone receptor modulator. | 2015-02-05 |
20150038477 | ORALLY ADMINISTRABLE GALLIUM COMPOSITIONS AND METHODS OF USE - Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium nitrate, together with certain viscosity-increasing agents, such as water-soluble forms of methylcellulose or carboxymethylcellulose. | 2015-02-05 |
20150038478 | BETA-LACTAMASE INHIBITORS - Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of 8 μg/mL or less against one or more isogenic β-lactamase expressing bacterial strains. | 2015-02-05 |
20150038479 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2015-02-05 |
20150038480 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME - The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same. | 2015-02-05 |
20150038481 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER - Described are compounds of Formula I or Formula II: wherein: ring A is a 5- or 6-membered heteroaryl group; dashed lines are optional double bonds; X is N or O; Y is a carbon atom or an S or N heteroatom in ring A in any suitable location; and substituents are as given herein. Compositions containing the same and methods of using the same in treating cancers such as acute lymphoblastic leukemia are also described. | 2015-02-05 |
20150038482 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2015-02-05 |
20150038483 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY - The present invention is related to a compound represented by formula (I) | 2015-02-05 |
20150038484 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK - The present invention relates to indole and indazole compounds of Formula (I) | 2015-02-05 |
20150038485 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES - The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 2015-02-05 |
20150038486 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY - Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. | 2015-02-05 |
20150038487 | METHODS OF TREATING HYPERTROPHIC CARDIOMYOPATHY - The present disclosure relates to a compound of formula (I) or formula (II) | 2015-02-05 |
20150038488 | SYK INHIBITORS - The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I | 2015-02-05 |
20150038489 | COMPOUND AND METHODS FOR TREATING LONG QT SYNDROME - Described herein is a method of treating long QT syndrome by administration of an effective amount of a potent and selective late sodium ion channel blocker | 2015-02-05 |
20150038490 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. | 2015-02-05 |
20150038491 | SOLID IVABRADINE-CONTAINING COMPOSITION - The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition. | 2015-02-05 |